MetaCap

HUTCHMED (China) (HCM) vs Lakefront Biotherapeutics (LKFT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lakefront Biotherapeutics (LKFT) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 8.6% versus a loss of 5.6%. Over five years, LKFT leads with a -31.8% price change compared with -62.4% for HCM. HUTCHMED (China) is the larger company by market cap ($2.30 billion vs $2.18 billion), about 1.1 times the size.

On valuation, Lakefront Biotherapeutics trades at a lower trailing P/E (2.4x vs 132.2x for HUTCHMED (China)).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCM-5.57%LKFT+8.64%
+17%-7%-31%
Nov 21, 20251 yearNov 20, 2026
HCM-56.97%LKFT-35.27%
+42%-19%-80%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCM versus LKFT key metrics
MetricHCMLKFT
Share price$13.22$33.31
Market cap$2.30B$2.18B
1-day change-1.71%-0.24%
YTD return-0.83%+1.87%
1-year return-5.57%+8.64%
5-year return-62.42%-31.80%
P/E ratio (TTM)132.202.39
Forward P/E51.00—
EPS (TTM)$0.10$13.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$548.51M—
Revenue growth (YoY)-12.96%—
Net income (latest FY)$456.91M—
Gross margin38.68%—
Operating margin-7.14%—
Net margin83.30%—
52-week high$16.33$36.24
52-week low$9.77$25.68
Distance from 52-week high-19.04%-8.08%
Analyst consensusnonehold
Avg. price target upside+59.91%-7.39%
Average volume64.48K280.49K
Shares outstanding173.81M65.48M
Employees1,790196
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LKFT has outperformed HCM by 14.2 percentage points over the past year.
  • HUTCHMED (China) trades at a higher earnings multiple (132.2x vs 2.4x trailing P/E).

About HUTCHMED (China)

HCM stock →

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees

About Lakefront Biotherapeutics

LKFT stock →

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees

HCM vs LKFT FAQ

Which is bigger, HUTCHMED (China) or Lakefront Biotherapeutics?

HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.30B compared with $2.18B for Lakefront Biotherapeutics (LKFT).

Which stock has performed better over the past year, HCM or LKFT?

LKFT returned +8.64% over the past 12 months, compared with -5.57% for HCM (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, HCM or LKFT?

LKFT has the lower trailing P/E at 2.4, versus 132.2 for HCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are HUTCHMED (China) and Lakefront Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons